ClinicalTrials.Veeva

Menu

Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders

H

Hospital Universitario Dr. Jose E. Gonzalez

Status and phase

Unknown
Phase 2
Phase 1

Conditions

Autism Spectrum
Autism

Treatments

Other: Stem cells

Study type

Interventional

Funder types

Other

Identifiers

NCT01740869
Autism uanl (Other Identifier)
HE12-021

Details and patient eligibility

About

The purpose of this study is to determine whether the plasticity of autologous intrathecal hematopoietic cells would improve the neurologic and the social skills of pediatric patients with autism spectrum disorders.

Full description

There is accumulating evidence that shows that the administration of hematopoietic cells into the brain in the patients with spectrum autism could help in the physiopathology of the illness.

It has been found that after introducing hematopoietic cells in the subarachnoid space of the spinal cord, these cells may be transported through the cerebrospinal fluid and can be delivered more efficiently to the injured area, when compared to the intravenous route.

Patients will be stimulated for 3 consecutive days with granulocyte colony stimulating factor (G-CSF) and then their bone marrow will be harvested according to their weight. Bone marrow will be processed in order to obtain CD34+ cells and minimize the amount of red blood cells. An inoculum of 5 to 10mL of stem cells will be infused intrathecally. Patients will be evaluated with two scales "CARS" and the "IDEA" also we will check the clinical history. On days 0, 30 and 180.

Enrollment

30 estimated patients

Sex

All

Ages

5 to 15 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • children with autism spectrum DSM4-TR

Exclusion criteria

  • Patients with neurodegenerative or autoimmune diseases.
  • Patients with active infection in any organ or tissue at the time of entering the study, the onset of stimulation with G-CSF or at the procedure.
  • Patients who do not sign the informed consent form.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

30 participants in 2 patient groups

Experimental: Patients
Experimental group
Description:
Children who will receive intrathecal autologous stem cells
Treatment:
Other: Stem cells
Control/Crossover
Other group
Description:
We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time.
Treatment:
Other: Stem cells

Trial contacts and locations

1

Loading...

Central trial contact

Laura Villarreal-Martinez, MD; Consuelo Mancias-Guerra, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems